NVO
Novo Nordisk A/S
NVO has lower modeled downside risk, despite its lower overall score.
RPID
Rapid Micro Biosystems, Inc.
RPID has a slight edge over NVO overall, supported by stronger fundamentals and stronger modeled upside.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
RPID Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Weak | |
| Unavailable |
RPID's revenue is currently healthy, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO's PE is 10x, but its earnings don't support one, so it isn't a reliable read right now.
RPID PE Valuation
RPID has no meaningful PE right now: it lost money over the past year.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
RPID Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect RPID's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO has the edge over RPID on earnings quality, reporting a profit while its opponent remains loss making.
RPID Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$1.10 | -$0.09 |
| Q1 2026 | -$1.10 | -$0.07 |
| Q4 2025 | -$1.05 | +$0.03 |
| Q3 2025 | -$1.01 | +$0.11 |
| Q2 2025 | -$1.01 | +$0.16 |
| Q1 2025 | -$1.03 | +$0.18 |
| Q4 2024 | -$1.08 | +$0.14 |
| Q3 2024 | -$1.12 | +$0.23 |
RPID is still losing money, but less than at its worst: $1.10 per share over the past year, against $1.62 at its worst in early 2021.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO's revenue is growing: $11.7B last quarter, up 2.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over RPID on profitability, with a higher operating margin.
RPID Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $8.1M | +11% |
| Q1 2026 | $8M | +11% |
| Q4 2025 | $11.3M | +37% |
| Q3 2025 | $7.8M | +3.1% |
| Q2 2025 | $7.3M | +9.7% |
| Q1 2025 | $7.2M | +28% |
| Q4 2024 | $8.2M | +30% |
| Q3 2024 | $7.6M | +24% |
RPID has the edge over NVO on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -153% | +14 points |
| Q1 2026 | -173% | -11 points |
| Q4 2025 | -108% | +16 points |
| Q3 2025 | -145% | +13 points |
| Q2 2025 | -167% | +35 points |
| Q1 2025 | -162% | +93 points |
| Q4 2024 | -124% | +68 points |
| Q3 2024 | -158% | +77 points |
RPID's operating margin was −153% last quarter, up 14 points from the same quarter a year ago.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO has the edge over RPID on cash generation, producing positive trailing cash flow while its opponent burns cash.
RPID Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$12.5M | -$2.4M |
| Q1 2026 | -$15.5M | -$6.1M |
| Q4 2025 | -$3.3M | +$6.7M |
| Q3 2025 | -$9.1M | -$301K |
| Q2 2025 | -$10.1M | +$512K |
| Q1 2025 | -$9.4M | +$6.7M |
| Q4 2024 | -$10M | -$92K |
| Q3 2024 | -$8.8M | +$1.3M |
RPID has burned cash in almost every quarter: −$40M over the past year, against −$38M the year before.
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has the edge over RPID on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
RPID Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +6.4% | +2.9M shares |
| 1 year | +8.3% | +3.7M shares |
| 3 years | +12% | +5.3M shares |
| 5 years | +52% | +16.6M shares |
RPID has 48M diluted shares, up 8.3% from a year ago.
| Quarter | Spent |
|---|---|
| Q1 2021 | — |
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
RPID Net Leverage
RPID's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
RPID Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 24.6 | Oversold |
| Stochastic | 4.6 | Oversold |
RPID's weekly RSI is 25 (oversold) and its Stochastic is 5 (oversold).
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO is trading at 10x earnings, a 60% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
RPID PE vs Healthcare Sector
RPID has no meaningful PE right now: it lost money over the past year.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has the edge over RPID on trend strength, trading above more of its moving averages.
RPID Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.81 | 17% below |
| 20 week MA | $1.34 | 50% below |
| 50 week MA | $2.29 | 71% below |
| 100 week MA | $2.57 | 74% below |
| 200 week MA | $1.78 | 62% below |
RPID is in a downtrend: it's below all five of its weekly moving averages, and 62% below its 200-week average.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has the edge over RPID on returns for 2026, with the stronger performance.
RPID Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $24.1 | $11.3 | -53% |
| 2022 | $11.3 | $1.43 | -87% |
| 2023 | $1.43 | $0.74 | -48% |
| 2024 | $0.74 | $0.96 | +30% |
| 2025 | $0.96 | $2.98 | +210% |
| 2026 YTD | $2.98 | $0.67 | -78% |
RPID's yearly returns have swung widely, from +210% in 2025 to −87% in 2022. It's down 78% so far in 2026.